Locations
Shanghai, China · Pudong, Shanghai, China
industry
Biotechnology
Size
1 - 10 employees
Stage
Other
founded in
2019
Grit Bio is a Chinese cell therapy company founded in 2019. The company is developing Tumor-Infiltrating Lymphocyte (TIL) therapy programs to address the unmet medical needs and to improve the quality of life for patients with solid tumors. GT101 - Grit’s non-gene-modified TIL product manufactured using a proprietary process - is the first TIL product to receive Investigational New Drug (IND) approval in China and is currently in Phase 1 clinical trial. Grit Bio has established three core technology platforms for its TIL development: Staviral® - a retroviral system tailored for TIL engineering, Immut Finder® - a high-throughput screening platform identifying novel T-cell targets, and TIL Expansion Platform Stemtexp® that preferentially enriches TCM and TSCM populations of TIL. The company is currently developing potentially best-in-class gene-engineered TIL therapy based on these platforms.
Something looks off?